QRxPharma Limited (QRX)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today it's FREE! Already a member? Login now!

General Information
Company Name: QRxPharma Limited
Stock Code: QRX
Website: www.qrxpharma.com
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 3
Equiv. Shares (M): 164

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.016 $ 0.016 $ 0.019 $ 0.015 $ 0.016 116,160 0%

Current Broker Consensus Recommendation more
Recommendation: Strong Buy (1)
Recommendation Date: 20th Aug 2014
Brokers Surveyed: 1

Company Overview

Business Description:
QRxPharma Limited (QRX) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and abuse prevention products. QRX conducts its operations in Australia.

Strategy Analysis:
In 2012, QRX plan to implement pre-launch messaging strategy, identify key geographic areas of concentration, implement MoxDue pre-launch promotional message and begin recruitment of additional Actavis territory managers. Beyond 2012, QRX strategy is to expand the sales force to 150-200. QRxPharma reported net loss of $5.21m, up 7.87% for the half-year ended 31 December 2012. Revenue from ordinary activities were $2.24m, down 26.89% from last year. Basic and Diluted EPS were (3.6) cents compared to (4) cents last year. The net operating cash outflow was $6.04m compared to an outflow of $1.92m in the pcp. No dividend was declared.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -13.3 -8.5 -- 0.0 0.0 0.0 --
2013  A -10.1 -7.0 -- 0.0 0.0 0.0 --
2012  A -16.0 -11.2 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $174 M 3.0384 -0.3833 1.1602 6.2202 10.0869 4.6693 7.66 6.51 6.07
Mayne Pharma Group (MYX) $450 M 1.0457 0.3770 0.2668 24.4409 17.7494 14.0110 0.00 0.00 0.00
QRxPharma (QRX) $3 M -- -- -- -- -- -- 0.00 -- --

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
QRX -- -- 0.29 -- 4.21
Market 0.92 15.1 1.19 1.73 1.50
Sector 0.81 18.5 2.78 1.22 7.50

Name Position Start Date
Mr Bruce Alan Hancox Non-Executive Director 09 July 2014
Dr Richard Treagus Non-Executive Director 09 July 2014

Name Position
Edward Rudnic Chief Executive Officer
Edward M Rudnic Chief Operating Officer
Chris Campbell Company Secretary
M. Janette Dixon Vice President Global Business Development

Substantial Shareholders
Holding Name
14,403,120 (9.95%) Auckland Trust Company Limited (ATF Second Pacific Master Superannuation Fund)
18,822,019 (13.00%) Allan Gray Australia Pty Ltd
7,609,635 (5.26%) John Holaday

Calendar of Events
Date Event
25 September 2015 Report (Annual)
26 August 2015 Report (Prelim)
24 February 2015 Report (Interim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Unlisted Property Trusts

A property trust allows you to buy 'units' in an investment operated by a professional investment manager. This Guide will help you understand the risks and decide whether to invest your money.

More details...


Australian Share Market - Close Up

CMC Markets 11/11/2014 | The Australian share market is in a decision zone - and trading from here may set the direction for the rest of the year.

Prices slashed - everything must go!

Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 | “If you want to have a better performance than the crowd, you must do things differently from the crowd.” Sir John Templeton.

Aussie share market bulls now have company

Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 | Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.

The Importance of Ignoring the Noise of the Market

Carl Richards, director of investor education at the BAM Alliance 17/10/2014 | “As odd as it may sound, the sooner you start treating your investments like you treat life, the happier you’ll be with the outcome.”

You only dance twice

William H. Gross, Janus Capital Group 16/10/2014 | “Financial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding “minus” 10 basis points.”

The Big Picture - Australia 200 Index

CMC Markets 8/10/2014 | Share market indices around the globe are breaking down. While analysts cast around for reasons, it’s clear that a time factor is in play. Simply put, many investors “feel” a correction is overdue. How low could it go?


Sponsored Links